Protocol Ledger

NCT07288177 · Phase II · RECRUITING

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT07288177 sponsored by Genmab in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-30 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07288177
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07288177
Protocol FieldVerified Registry Value
NCT IdentifierNCT07288177
Consolidated Lead SponsorGenmab
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2026-01-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07288177
Hospital Research SiteLocationSite Profile
City of Hope Orange CountyIrvine, CAOpen Hospital Dossier ->
MedStar Georgetown University HospitalWashington D.C, DCOpen Hospital Dossier ->
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI